Basilea Pharmaceutica has revised its financial outlook upward for 2026, citing strong performance and ongoing sales growth for its key antifungal product, Cresemba.
The upward revision reflects positive commercial momentum for the treatment, which serves as a primary revenue driver for the company. Further details regarding the updated financial projections were not immediately disclosed.
